Development of Bispecific Antibodies: The Critical Role of Mouse Models

2024-10-24 232

Bispecific antibodies (BsAbs) are experiencing unprecedented growth, drawing the attention of major pharmaceutical companies and biotech firms worldwide. Recently, Merck & Co. (MSD) acquired the global rights to CD19/CD3 BsAb CN201 from Tolerogen Bio for $1.3 billion, underscoring the immense value of these innovative therapeutics in the market. BsAb technology, which targets two distinct molecules simultaneously, not only activates the immune system but also effectively eliminates tumor cells. This dual functionality demonstrates promising potential in the treatment of hematologic malignancies and immune-related diseases.

Fig 1. Mechanism of Action of Bispecific Antibodies

The development of bispecific antibodies (BsAbs) requires rigorous preclinical validation, and mouse bispecific antibodies play a pivotal role in this process. These antibodies are instrumental in the early screening and optimization of BsAb structures, ensuring both efficacy and safety of candidate drugs. They also lay a solid foundation for the subsequent development of humanized antibodies. As therapeutic strategies continue to evolve, mouse BsAbs provide new research pathways for enhancing the efficacy of bispecific drugs.

Key Role of Bispecific Antibodies (BsAbs) and Mouse Models

Bispecific antibodies are a unique class of antibodies capable of targeting two distinct molecules or antigens simultaneously. By bridging two targets, BsAbs can precisely direct immune cells to specific sites, such as tumor cells, and either activate or inhibit specific signaling pathways. This dual-targeting approach enhances therapeutic specificity and efficacy. BsAbs are widely used in various fields, including cancer immunotherapy, hematological disorders, and autoimmune disease interventions.

Mouse bispecific antibodies are specifically designed for use in mouse models, simulating their mechanism of action in human systems. They are critical tools in the early stages of drug development, facilitating the selection and optimization of candidate molecules. Due to their short development cycles, low costs, and the absence of immune rejection (common with non-mouse antibodies), mouse BsAbs provide essential support for the development of humanized antibodies, accelerating the launch of innovative therapeutics.

Fig. 2 Various Designs and Structures of Bispecific Antibodies

Advantages and Applications of Mouse Bispecific Antibodies

■Rapid Screening and Optimization:
Mouse BsAbs provide an efficient platform for fast antibody screening, thanks to their short development cycles.

■Cost-Effective and Easy to Use:
Compared to humanized antibodies, mouse BsAbs are more cost-effective, making them ideal for large-scale screening and analysis.

■Elimination of Immune Rejection:
Using mouse-derived antibodies in mouse models avoids immune rejection, ensuring experimental consistency and stability.

■Support for Humanized Antibody Development:
The data generated with mouse BsAbs provide critical insights for the subsequent development and validation of humanized antibodies.

Common Targets and Applications of Bispecific Antibodies

AntibodySystem Mouse BsAb Products and Services

To support proof-of-concept (POC) research, AntibodySystem has developed a series of mouse bispecific antibodies specifically for in vivo experiments. These products are available through authorized distributors and are accompanied by fast delivery services. In addition, AntibodySystem offers custom target design and bispecific antibody development services to meet diverse research needs.

■Fully Mouse-Derived Designs:
Avoid heterologous reactions, ensuring compatibility and stability in mouse models.

■IgG-Like Structures:
Provide enhanced stability and activity in experiments, ensuring reliable results.

■Low Endotoxin, High Purity:
Meets strict standards for in vivo studies, ideal for preclinical cancer research.

Recommended Mouse Bispecific Antibody (BsAb) Product List